Dieter and I had ,over the years , consumed numerous bottles of various red wines , discussing drug development and research in general and often AMRN in particular. Even tho we were "in different worlds " business wise , we had sons in the same class , and found we had many similar interests ( we were both on Statins , he had several stents from an earlier MI that he survived ) and in the last 6 yrs we were both very interested in advances in therapy
Probably our biggest "score " was PCYC which I found at around $30 a share and he researched it for me and decided they had a good chance of succeeding in their clinical trials . PCYC was eventually Bt out at around $240 ...altho I sold it at around $120 ( yes I'm half smart :-)
So yes we all expect to live a very long time , but Dieters unexpected passing reminds all of how fragile life can be.
His view on Reduce It was that it was unlikely to be stopped at the first interim ( for many of the reasons poster Vu mentions ) but he did expect it to show clinically meaningful benefit if it ran to completion.
I didn't sell my position ( currently only 5% of my portfolio ) ....will hold it until R-IT reads out . If we are above $3 by the time the conversion is complete I'll consider it a victory for AMRN mgt ( and shareholders ) Good luck Kiwi